Olema Pharmaceuticals (OLMA): Price and Financial Metrics
GET POWR RATINGS... FREE!
OLMA Stock Price Chart Interactive Chart >
OLMA Price/Volume Stats
| Current price | $4.71 | 52-week high | $7.41 |
| Prev. close | $4.74 | 52-week low | $2.00 |
| Day low | $4.46 | Volume | 106,400 |
| Day high | $4.99 | Avg. volume | 221,722 |
| 50-day MA | $3.11 | Dividend yield | N/A |
| 200-day MA | $3.48 | Market Cap | 190.54M |
Olema Pharmaceuticals (OLMA) Company Bio
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Latest OLMA News From Around the Web
Below are the latest news stories about OLEMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate OLMA as an investment opportunity.
Olema Pharmaceuticals Inc. (OLMA) is an excellent investment, but the stock is overvalued/undervalued right nowOlema Pharmaceuticals Inc. (NASDAQ:OLMA) marked $4.01 per share on Thursday, up from a previous closing price of $3.92. While Olema Pharmaceuticals Inc. has overperformed by 2.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OLMA fell by -45.29%, with highs and lows ranging from $7.41 to […] |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to three new employees to purchase an aggregate of 54,400 shares of the Company's common stock, effective as of January 3, 2023. These awards were approved by the Compensation |
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare ConferenceSAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET). |
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) Reduces -4.51% In A Week: What’s Lifting The Stock?In last trading session, Olema Pharmaceuticals Inc. (NASDAQ:OLMA) saw 0.4 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.33 trading at -$0.12 or -4.90% at ring of the bell on the day assigns it a market valuation of $95.79M. That closing price of OLMA’s stock is … Olema Pharmaceuticals Inc. (NASDAQ:OLMA) Reduces -4.51% In A Week: What’s Lifting The Stock? Read More » |
OLMA Price Returns
| 1-mo | 89.92% |
| 3-mo | 26.95% |
| 6-mo | -4.85% |
| 1-year | -19.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 92.24% |
| 2022 | -73.82% |
| 2021 | -80.53% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...